European Medicines Agency will consider therapy for the treatment of patients with multiple myeloma
News
Antibody discovered by RQ Bio enters pivotal research phase
AstraZeneca trial will study activity of AZD5156 which includes monoclonal antibody discovered by RQ Bio
Valneva delivers additional data for COVID-19 booster vaccine
Company has reported booster details from a study of its inactivated COVID-19 candidate
Orion and Alligator reveal second stage of immuno-oncology research collaboration
Second study will develop a bispecific antibody with potential applications in solid tumours
Gilead reveals positive results for domvanalimab
Study uses carious drug combinations to increase survival among lung cancer patients
Multi-million-pound funding for genomics research
Vital financing will help boost diagnosis, treatment and prospects of patient groups
EQRx receives MHRA marketing approval for sugemalimab
Therapy treats patients with metastatic non-small cell lung cancer and has completed successful phase 3 trial
AlzeCure’s promising Alzheimer’s abstract accepted
ACD856 has also been shown across preclinical studies to improve cognition and memory
Verona Pharma’s ensifentrine meets COPD objectives
Therapy shows quality of life boost and significant improvement in lung function
Mainz recruits first patient into biomarker research
ColoAlert research could identify advanced adenomas among colorectal cancer patients
hVIVO delivers promising results for Imutex’s mosquito vaccine
AGS-v PLUS contains five synthetic peptides that originate from proteins found in mosquito saliva
AstraZeneca’s Forxiga recommended in EU for chronic heart failure
Drug is the first heart failure medication to provide mortality benefit across entire ejection fraction range
CHMP issues positive opinion for CSL’s etranacogene dezaparvovec
Gene therapy involves adults with haemophilia B and brings renewed hope to patients across Europe
Pfizer and Anumana boost detection of cardiovascular disease
Partnership will support development of new algorithm and identify at risk patients
MinervaX reveals financing to development group B streptococcus vaccine
Plans include phase 3 clinical development of novel GBS vaccine and an efficacy evaluation
